Table-II.

Association between VEGF gene polymorphisms and risk of osteosarcoma.

SNPs	Genotype	Osteosarcoma group	%	Control group	%	OR(95%CI)1	P value
-2578C/A	CC	62	35.3	84	47.5	1.0(Ref.)	-
	CA	78	44.2	71	40.1	1.49(0.92-2.42)	0.09
	AA	36	20.5	21	12.4	2.32(1.18-4.60)	<0.05
	CA+AA	114	64.7	92	52.5	1.68(1.07-2.64)	<0.05
-1156G/A	AA	93	52.6	97	55.3	1.0(Ref.)	-
	AG	73	41.3	71	40.2	1.07(0.68-1.69)	0.75
	GG	11	6.1	8	4.5	1.43(0.50-4.30)	0.46
	AG+GG	84	47.4	79	44.7	1.11(0.71-1.72)	0.63
+1612G/A	CC	77	43.5	80	45.7	1.0(Ref.)	-
	CT	80	45.4	78	44.2	1.07(0.67-1.70)	0.78
	TT	19	11.1	18	10.1	1.10(0.50-2.40)	0.80
	CT+TT	99	56.5	96	54.3	1.07(0.69-1.67)	0.75
+936C/T	CC	85	48.2	92	52.4	1.0(Ref.)	-
	CT	75	42.3	71	40.1	1.14(0.72-1.82)	0.55
	TT	16	9.5	13	7.5	1.39(0.59-3.33)	0.41
	CT+TT	91	51.8	84	47.6	1.17(0.76-1.82)	0.46
-634G/C	CC	61	34.6	67	38.1	1.0(Ref.)	-
	CG	85	48.2	81	46.2	1.15(0.71-1.88)	0.55
	GG	30	17.2	28	15.7	1.18(0.60-2.30)	0.61
	CG+GG	115	65.4	109	61.9	1.16(0.73-1.83)	0.51
-460T/C	TT	48	28.4	66	37.3	1.0(Ref.)	-
	TC	89	50.3	85	48.2	1.44(0.87-2.39)	0.13
	CC	39	21.3	25	14.5	2.15(1.10-4.21)	<0.05
	TC+CC	128	71.6	110	62.7	1.60(1.0-2.58)	<0.05

¹Adjusted for sex, age and family history of cancer.